A detailed history of E Fund Management Co., Ltd. transactions in United Therapeutics Corp stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 3,204 shares of UTHR stock, worth $1.16 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
3,204
Previous 3,908 18.01%
Holding current value
$1.16 Million
Previous $1.24 Million 7.72%
% of portfolio
0.06%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$311.04 - $363.55 $218,972 - $255,939
-704 Reduced 18.01%
3,204 $1.15 Million
Q2 2024

Aug 12, 2024

BUY
$228.26 - $319.04 $485,052 - $677,960
2,125 Added 119.18%
3,908 $1.24 Million
Q1 2024

May 13, 2024

SELL
$210.76 - $249.51 $43,205 - $51,149
-205 Reduced 10.31%
1,783 $409,000
Q4 2023

Feb 06, 2024

SELL
$214.88 - $256.94 $9,454 - $11,305
-44 Reduced 2.17%
1,988 $437,000
Q3 2023

Nov 13, 2023

BUY
$211.82 - $248.24 $16,310 - $19,114
77 Added 3.94%
2,032 $459,000
Q2 2023

Aug 11, 2023

BUY
$205.19 - $232.99 $54,580 - $61,975
266 Added 15.75%
1,955 $432,000
Q1 2023

May 11, 2023

BUY
$212.99 - $276.17 $38,551 - $49,986
181 Added 12.0%
1,689 $378,000
Q4 2022

Feb 14, 2023

SELL
$205.95 - $280.43 $128,306 - $174,707
-623 Reduced 29.24%
1,508 $419,000
Q3 2022

Nov 14, 2022

BUY
$203.3 - $244.17 $29,681 - $35,648
146 Added 7.36%
2,131 $446,000
Q2 2022

Aug 15, 2022

BUY
$174.81 - $241.14 $75,867 - $104,654
434 Added 27.98%
1,985 $468,000
Q1 2022

May 12, 2022

BUY
$166.16 - $213.96 $113,321 - $145,920
682 Added 78.48%
1,551 $278,000
Q1 2021

May 12, 2021

BUY
$153.94 - $174.85 $133,773 - $151,944
869 New
869 $145,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.5B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.